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Abstract  
Purpose: Fibroblast growth factor-21 (FGF-21) appears to have an important role in glucose and lipid 
metabolism. FGF-21 secretion is mainly determined by nutritional status. The aim of this study was to measure 
basal and postprandial FGF-21 and postprandial change of FGF-21 concentration in type 1 diabetes mellitus 
(T1DM) patients and in healthy controls and to investigate the differences between the groups.  
Methods: The cross-sectional study included 30 C-peptide negative T1DM patients, median age 37 years (20-
59), disease duration 22 years (3-45), and 9 healthy controls, median age 30 years (27-47). Basal and 
postprandial FGF-21 concentrations were measured by ELISA. The associations of FGF-21 with glucose, lipids 
and insulin were analyzed. 
Results: Individuals with T1DM showed significantly lower basal FGF-21 concentration (P=0.046) when 
compared with healthy controls (median value 28.2 vs 104 pg/mL) and had significantly different postprandial 
change (∆ 30’-0’) of FGF-21 (P=0.006) in comparison with healthy controls (median value -1.1 vs -20.5 pg/mL). 
The glucose and lipid status did not correlate with FGF-21.  In healthy controls, postprandial insulin level 
correlated with basal FGF-21 (ρ=0.7, P=0.036). Multiple regression analysis showed that they are independently 
associated after adjustment for confounding factors (β=1.824, P=0.04). 
Conclusion: We describe the pathological pattern of basal and postprandial change of FGF-21 secretion not 
associated with glucose, lipid levels or insulin therapy in patients with T1DM. Since FGF-21 has numerous 
protective metabolic effects in the experimental model, the lower basal FGF-21 concentration in T1DM patients 
opens the question about the potential role of recombinant FGF-21 therapy.  
Key-words: fibroblast growth factor-21, type 1 diabetes mellitus, C-peptide negative, healthy controls. 
 
 
 
 
 
 
3 
 
Introduction 
Fibroblast growth factor-21 (FGF-21) has been recently recognized as a novel metabolic regulator with an 
important effect on glucose and lipid metabolism. Kharitonenkov et al. [1] first discovered that FGF-21 
stimulates glucose uptake in vitro in primary culture of human adipocytes. The numerous positive effects of 
FGF-21 in vivo were proven somewhat later. Contrary to expectations, higher FGF-21 concentrations were found 
in patients with type 2 diabetes mellitus (T2DM), obesity and metabolic syndrome [2-7]. The results were 
explained by potential FGF-21 resistance [8,9] or compensatory protective elevation of FGF-21 [10,11]. FGF-21 
is considered a metabolic protector, but its true physiological effects in humans remain unclear. FGF-21 is 
predominantly secreted by the liver, adipocytes and the pancreas. Circulating FGF-21 after a meal exerts a 
number of effects on metabolically active organs [12,2,13]. Metabolic crisis (starvation and overfeeding) is the 
greatest stimulus for FGF-21 secretion, which may be explained by excessive levels of free fatty acids that 
induce FGF-21 secretion [14,15].  
So far, only one study  explored basal serum FGF-21concentration in newly diagnosed T1DM patients, 
describing markedly lower FGF-21 in comparison with healthy population, T2DM and latent autoimmune 
diabetes in adults [16]. The authors proposed that the autoimmune process destroys pancreatic β-cells and 
consequently reduces FGF-21 secretion in T1DM. They also found an inverse link between serum FGF-21 
concentration and titer of pancreatic islet cell antibodies, and a positive relationship between serum FGF-21 and 
C-peptide concentration.  
Furthermore, one study reported on a decrease in postprandial FGF-21 concentration after oral fat load in healthy 
subjects and  postulated  that it was modulated by postprandial accumulation of triglyceride-rich lipoprotein 
fractions [17]. Another study examined changes in FGF-21 concentration, glucose, insulin and C-peptide levels 
after 75-g oral glucose tolerance test in healthy subjects, people with impaired glucose tolerance and patients 
with T2DM, respectively. They found that FGF-21 concentrations declined in the first 60 minutes and then 
increased until the 180th minute in all 3 examined groups, and that changes in serum FGF-21 at different time 
points were inversely associated with changes in insulin and C-peptide levels only in healthy subjects but not in 
two other groups [18].  
Postprandial concentrations and changes of serum levels of FGF-21 in T1DM patients have not been studied so 
far. Although a previously published Chinese study [16] showed a decreased basal FGF-21 in T1DM, the basal 
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serum FGF-21 concentration in long standing T1DM patients without residual pancreatic β-cell function has not 
been studied so far.  
The primary aim of the study was to measure basal FGF-21, postprandial FGF-21 and postprandial change in 
FGF-21 concentration in long standing T1DM C-peptide negative patients and their matched healthy controls, 
and to explore the difference in the FGF-21 concentrations between the two examined groups. We also examined 
if glucose and insulin levels or insulin therapy and lipid profile status correlated with FGF-21 concentration. The 
secondary aim was to investigate whether there was a gender difference in FGF-21 within the studied groups. 
Our results could additionally clarify the pathophysiology not only of basal, but also postprandial FGF-21 
concentration and postprandial change in FGF-21 in T1DM patients. We presumed that healthy people expressed 
a normal pattern of FGF-21 secretion. 
Materials and Methods  
Study design and subjects 
The cross-sectional study included 30 C-peptide negative T1DM patients and 9 healthy volunteer controls. The 
patients were selected from the annual review at Vuk Vrhovac University Clinic for Diabetes, Endocrinology 
and Metabolic Diseases, Zagreb, Croatia. The diagnosis of T1DM was defined according to the World Health 
Organization criteria [19]. The inclusion criteria for the T1DM patients were as follows: 18-65 years of age, at 
least 1-year duration of T1DM, no history of cardiovascular, severe liver or chronic kidney disease, with 
glomerular filtration rate > 45 mlmin-11.73-1m2 and without adrenal insufficiency. The patients received intensive 
insulin therapy (long-acting insulin in one or two doses and ultrashort-acting insulin three times daily) and took 
no other medication that could affect glucose or lipid metabolism. Nine age, gender and body mass index (BMI) 
matched people were included as the healthy control group (without diabetes mellitus, without history of 
cardiovascular, severe liver or chronic kidney disease, with glomerular filtration rate > 45 mlmin-11.73-1m2 and 
without adrenal insufficiency). The Ethics Committee of University of Zagreb School of Medicine and Hospital 
approved the study protocol. Written informed consent was obtained from each examinee, and the study was 
performed in accordance with the Declaration of Helsinki.  
Detailed medical history, including age at diabetes diagnosis, type of insulin therapy and other medications were 
obtained. Physical examination included measuring the body weight and calculation of BMI. All investigations 
were performed in the morning, following an overnight fast of 12 hours. All patients received long-acting insulin 
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the night before and ultrashort-acting insulin before breakfast. Fasting venous blood samples were drawn at 8:00 
AM and 30 minutes postprandial (we wanted to examine whether serum FGF-21 concentration is responsive to 
acute metabolic changes after the breakfast load which consisted mostly of carbohydrates), after a standard 
diabetic breakfast, both in T1DM and in healthy subjects: a mixed meal of low fat milk, black bread, low fat ham 
and fruit. The caloric value of the meal depended on the subject’s weight and consisted of 70% carbohydrates, 
25% proteins and 5% fat (glycemic index of the breakfast was in the range from 185-260). Venous blood 
samples (plasma and serum) were collected for biochemistry panel measurement, glycated hemoglobin (HbA1c), 
lipid profile, C-peptide level, insulin level and basal and postprandial FGF-21 concentration. The insulin levels 
in T1DM patients were not analyzed as we included patients without endogenous insulin secretion, so only 
exogenous administration of insulin would be measured, and it varied widely among the subjects. Thus, in 
T1DM patients the total daily insulin requirement and short-acting insulin requirement were measured. All 
samples were adequately stored at -70 C, from the collection time until analysis. 
Laboratory Assays 
Biochemistry panel, C-peptide, insulin level, HbA1c, lipid profile, pancreatic islet cell antibodies and serum 
creatinine concentration were assayed using routine laboratory methods. Serum FGF-21 concentration was 
measured using ELISA (sandwich) commercial kit (Human FGF-21 Immunoassay Kit, ALPCO, USA); 
photometer STATFAX 2100. According to the manufacturer, the range of detection was 30 pg/mL -1920 pg/mL 
and the intra-assay coefficients of variability (CV) were 4% at 93.3 pg/mL and 5% at 547 pg/mL; inter-assay CV 
of 10.2% at 273.5 pg/mL and 3.5% at 335 pg/mL, with no cross-reactivity with mouse FGF-21. Sensitivity was 
10.4 pg/mL. Postprandial change in hormone concentration was calculated as the difference between 
postprandial and basal hormone concentration, expressed as delta (∆). 
Statistical Analysis 
Statistical analysis was done using Statistical Package for the Social Sciences (SPSS) ver. 17.0 for Windows. 
Because of the small sample size the variables were described as median and minimum-maximum range and 
nonparametric statistical tests were used. Descriptive statistics presented nominal variables as proportions. The 
difference between two independent numerical variables was tested using the Mann-Whitney test and two 
dependent variables using the Wilcoxon test. Correlation analysis was performed using Spearman test. Multiple 
linear regression analysis was performed to examine the association of basal FGF-21 with postprandial insulin 
level in healthy subjects after adjustment for possible confounding factors (age, gender, fasting insulin, 
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triglycerides and LDL concentrations). Binary logistic regression analysis was performed to examine the 
difference in FGF-21 concentration between the T1DM patients and healthy controls, after adjustment for 
possible confounding factors (age, gender, BMI and postprandial glucose), (Hosmer-Leveshow goodness-of-fit 
test, using OR with 95% CI). Significance level was accepted at P<0.05.  
Results 
The basic clinical and laboratory characteristics of T1DM patients and healthy controls are summarized in Table 
1. The gender distribution was almost equal, with median age of 37 (T1DM patients) and 30 years (healthy 
controls), and median disease duration of 22 years. The T1DM patients were C-peptide negative; the basal C-
peptide concentration was 0 nmol/L (0-0.11) and postprandial C-peptide was 0 nmol/L (0-0.35). The total daily 
insulin requirement was 0.6 IU/kg (0.3-0.9). One patient had the value of fasting FGF-21 of 842.4 pg/mL and 
postprandial FGF-21 of 946 pg/mL, so those concentrations were not reported in the graph (Figure 1.), but were 
included in statistics (she was 25 years, 10 years of T1DM duration, BMI 23 kg/m2, HbA1c value 10.3%, total 
daily insulin requirement 0.9 IU/kg, fasting glucose value 13.1 mmol/L and postprandial of 4.7 mmol/L). There 
was no statistically significant difference in fasting glucose concentration (P=0.077) between the groups. 
Besides the expected higher postprandial glucose concentration (P=0.001) and HbA1c level (P<0.001), 
individuals with T1DM had significantly lower basal FGF-21 concentration (P=0.046) when compared with 
healthy controls (median value 28.2 vs 104 pg/mL) and had significantly different postprandial change (∆ 30’-0’) 
in FGF-21 (P=0.006) in comparison with healthy controls (median value -1.1 vs -20.5 pg/mL). There was no 
difference in postprandial FGF-21 concentration between the groups (P=0.217). Postprandial change, ∆ FGF-21 
was significantly decreased (negative) in healthy controls. There was no significant difference in other metabolic 
parameters between the two studied groups. 
Figure 1. shows the significant difference between the basal and postprandial FGF-21 concentration in healthy 
controls (104 vs 66 pg/mL; P=0.011). The difference between basal and postprandial FGF-21 was not found in 
T1DM patients (28.2 vs 28.25 pg/mL, P=0.974) (Figure 1.). There was a big difference between the fasting and 
postprandial glucose level (P<0.001) in T1DM patients, but no difference was found in healthy subjects 
(P=0.086) although there was a significant difference between basal and postprandial insulin levels in healthy 
subjects (P=0.008). There was no significant correlation between FGF-21 levels and HbA1c, fasting and 
postprandial glucose levels, total daily and short-acting insulin requirement, fasting and postprandial lipid profile 
status and the titer of pancreatic islet cell antibodies in T1DM patients (data not shown). Also, there was no 
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significant correlation between FGF-21 levels and HbA1c, fasting insulin level, fasting and postprandial glucose 
level and fasting and postprandial lipid profile status in healthy controls (data not shown). In healthy controls, 
postprandial insulin level significantly positively correlated with basal FGF-21 concentration (ρ=0.7, P=0.036). 
In multiple regression analysis, postprandial insulin concentration in healthy subjects remained independently 
associated with basal FGF-21 concentration (β=1.824, P=0.04), after adjustment for possible confounding 
factors: age, gender, fasting insulin level, fasting triglyceride and LDL concentrations. 
In order to examine independent difference in basal FGF-21 concentration and postprandial change in FGF-21 
between T1DM patients and healthy controls, binary logistic regression analysis with the studied group as 
dependent variable (T1DM patients vs healthy controls) and age, gender, BMI and postprandial glucose 
concentration as independent variables (possible confounders) was performed (Table 2.). Basal FGF-21 
concentration did not remain significantly higher in healthy controls, but ∆ FGF-21 remained independently 
decreased in healthy controls (OR 0.942, 95% CI 0.891-0.997, P=0.04) after adjustment for age, gender and 
BMI, but not after adjustment for all three parameters and postprandial glucose concentration (P=0.135). 
In order to explore gender difference in FGF-21 concentration in T1DM patients and in healthy controls the 
Mann-Whitney test was performed. The results showed that women with T1DM had significantly higher basal 
FGF-21 concentration in comparison with T1DM men (51.4 pg/mL, 13.1-842.4 vs 21.1 pg/mL, 0-124.8; 
P=0.042), but only in univariate model. In healthy controls no gender-related difference in FGF-21 concentration 
was found (data not shown). 
Discussion 
We found a significant difference in basal FGF-21 concentration and postprandial change in FGF-21 between 
T1DM patients and healthy controls. T1DM patients had significantly lower basal FGF-21 when compared with 
healthy controls using univariate analysis. Healthy controls had independently significant postprandial fall (∆) in 
FGF-21 concentration after adjustment for age, gender and BMI in comparison with T1DM patients, but not 
after adjustment for postprandial glucose level. The glucose concentration did not show any correlation with 
FGF-21 concentration in either group of subjects, but univariate statistics showed significant difference in 
postprandial glucose concentration between the healthy controls and T1DM patients (6.2 vs 11.2 mmol/L). 
Glucose was described as one of the major factors that influenced FGF-21 secretion [14], and carbohydrates 
were the major constituents of the diet in our study. The postprandial FGF-21 concentration did not differ from 
the basal value in T1DM patients. Lipid profile status also did not show any correlation with FGF-21 level in 
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either group, while basal FGF-21 showed independently positive correlation with postprandial insulin level in 
healthy subjects in multivariate analysis.  
The authors of a Chinese study reported on the basal FGF-21 concentration in T1DM patients [16]. They found a 
significantly decreased basal FGF-21 concentration in T1DM patients compared to healthy controls. Their group 
of T1DM patients (N=76) had a higher basal median FGF-21 concentration in comparison with our T1DM 
patients, but still significantly lower than their healthy controls. The Chinese study included mostly women of 
younger age and with newly diagnosed C-peptide positive T1DM (within one year). In our study, the patients 
were C-peptide negative, which could explain the lower basal FGF-21 concentration in our T1DM group of 
patients in comparison with the Chinese group. The authors of the Chinese study hypothesize that autoimmune 
destruction of pancreas could be the cause of impaired FGF-21 secretion in T1DM. The Chinese study also 
described the inverse correlation between FGF-21 level and the titer of pancreatic islet cell antibodies, while we 
did not find any correlation. Furthermore, in comparison with the Chinese group of patients, our patients mostly 
had long standing T1DM, with fewer patients positive for pancreatic islet cell antibodies, which can also be 
explained by the longer average duration of autoimmune diabetes in our group of patients.  Xiao et al. did not 
examine the correlation between FGF-21 level and glucose and lipid profile status or insulin therapy. Although 
our finding of lower basal FGF-21 supports the previous Chinese report, our study is the first study of basal 
serum FGF-21 concentration in long standing T1DM European patients without residual pancreatic β-cell 
function.  
The study of Matikainen et al. [17] described a decrease in FGF-21 serum concentration in healthy subjects 4 
hours after oral fat load and regress to basal values after 8 hours. In their study FGF-21 postprandial 
concentrations inversely correlated with triglyceride-rich lipoprotein fractions in large VLDL, but not with 
plasma free fatty acids. This was the first report in humans and they hypothesized that both fasting and 
postprandial chylomicron and VLDL particles were better predictors of FGF-21 than fasting free fatty acids, and 
that suppression of FGF-21 regulates postprandial lipid metabolism and permits better clearance of triglyceride-
rich lipoprotein fractions [17]. In our study, we did not find any correlation between fasting and postprandial 
FGF-21 with fasting and postprandial glucose and lipid status in either group studied. A positive correlation was 
only found between basal FGF-21 and postprandial insulin level in healthy subjects, which supports the role of 
FGF-21 as a potential metabolic regulator in humans. To date, little is known about FGF-21 in patients with 
T1DM, especially about postprandial FGF-21. Available data is not yet sufficient to explain the mechanism of 
the results. 
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The study of Lin et al. [18] described the dynamic change of serum FGF-21 in healthy subjects, in subjects with 
impaired glucose tolerance and in subjects with T2DM in response to oral glucose tolerance test, respectively. 
Acute metabolic change showed that FGF-21 concentrations decrease in 60 minutes in all 3 groups of subjects 
and progressively increase until the 180th minute. The decrease in FGF-21 was significantly smaller in the 2 
groups of patients than in healthy controls at the first 60 minutes of oral glucose tolerance test. Furthermore, they 
found an inverse correlation between the fold changes in FGF-21 and insulin and C-peptide levels only in 
healthy controls, suggesting that abnormal FGF-21 production in response to glucose may be related to impaired 
insulin secretion or resistance in patients with impaired glucose tolerance and T2DM, respectively [18]. In our 
study with C-peptide negative T1DM patients we showed a lack of FGF-21 suppression after the breakfast load 
at 30 minutes, suggesting abnormal FGF-21 production in T1DM patients in response to acute metabolic change. 
One study by Yang et al. [20] demonstrated that elevation of insulin acutely suppressed FGF-21 production. 
Consequently, we measured FGF-21 postprandial concentration at 30 minutes, after an ultrashort-acting insulin 
application in T1DM patients, but there was no association between insulin therapy and postprandial FGF-21 
secretion. Our healthy controls showed normal FGF-21 production in response to meal load at 30 minutes: FGF-
21 levels decreased significantly.  
The study of Kralisch et al. [21] demonstrated statistically positive (although weak) correlation of FGF-21 with 
metabolic syndrome parameters in healthy controls. They also described significantly higher FGF-21 
concentration in T2DM patients in comparison with healthy controls, but did not study correlation of FGF-21 
with metabolic syndrome parameters in T2DM group of patients. In our healthy controls we found no correlation 
of FGF-21 with glucose or lipid profile status, but we studied only 9 healthy controls compared with 670 healthy 
controls in their study. 
To date, there is no study describing postprandial change in FGF-21concentration in T1DM patients and 
comparing it with healthy subjects. During the fasting period, in metabolic crisis, free fatty acids induce FGF-21 
secretion. That is probably the cause of normally higher basal FGF-21 concentration in healthy controls. 
However, in the postprandial period, FGF-21 secretion is not induced by free fatty acids, which could explain 
lower postprandial FGF-21 concentration in healthy controls.  Based on our results, we believe that healthy 
people expressed a physiological pattern of FGF-21 secretion, which was lost in T1DM. There was no 
postprandial change/fall in FGF-21 concentration in T1DM patients; the postprandial FGF-21 concentration was 
equal to basal. As far as we know, there is no study comparing basal and postprandial FGF-21 concentration, and 
dealing with postprandial FGF-21 change in T1DM patients so we are not able to compare our results. A large 
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reference range observed in FGF-21 concentrations was also supported by other studies among healthy subjects 
and patients [22,5,23]. It was suggested that the FGF-21 concentrations peak in the early morning, after an 
overnight fast and thereafter oscillate parallel to the changes in concentrations of free fatty acids [15]. 
In the present study we found a significantly higher basal FGF-21 concentration in women in comparison with 
men with T1DM, but in univariate model. It is possible that our findings could additionally explain why the 
Chinese group of patients (mostly women) had higher basal FGF-21 concentration than our group (where gender 
distribution was almost equal). In healthy controls there was no gender difference in FGF-21 concentration. 
There is no published study in T1DM patients that describes gender difference in FGF-21 concentration. 
Available data on gender differences in FGF-21 concentration in non-diabetic population vary widely: from 
equal FGF-21 concentration [24,25] to lower [21] and higher FGF-21 concentration in women [26,27].  
The higher FGF-21 concentration was recently described in girls and  explained it by higher triglycerides levels 
[27]. In our study there was no difference in triglycerides between the genders. Maybe the difference in sex 
hormones could explain the gender difference in FGF-21 in T1DM patients or it might be closely related to the 
pathology of the disease. 
We have to emphasize the strengths and limitations of our study. We included T1DM patients without residual 
β-cell function (C-peptide negative). Our sample was therefore more homogenous and we could eliminate 
endogenous insulin impact on FGF-21 concentrations. All subjects were adults, of same race (and presumed 
eating tradition), without significant difference in gender prevalence, and all subjects were controlled in one 
center with standardized therapeutic approach; thus our results could be considered region specific. On the other 
hand, it was a cross-sectional study, which restricted the ability to establish causality. We did not measure 
hormones in duplicates and blood was collected only once.  The results could not be generalized for the whole 
population of healthy individuals because of the limited number of control participants. Therefore, we were 
limited by relying on the resulted data.  
In conclusion, we describe the pathological pattern of basal and postprandial change of FGF-21 secretion not 
associated with glucose, lipid levels or insulin therapy in patients with T1DM. T1DM patients had lower basal 
FGF-21 concentration in comparison with healthy subjects. Healthy controls had an expectedly negative 
postprandial change in FGF-21 in comparison with T1DM patients, which could be explained by the 
physiological pattern of FGF-21 secretion in healthy people. The glucose and lipid profile status, insulin therapy 
and fasting insulin levels did not correlate with FGF-21 concentration in either studied group. Thus we 
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hypothesized that autoimmune destruction of pancreas could be contributing to impaired FGF-21 secretion in 
T1DM. Since FGF-21 has numerous protective metabolic effects, so far confirmed in experimental models 
[28,29], lower FGF-21 concentration in T1DM patients opens the question about the potential role of 
recombinant FGF-21 therapy in patients with T1DM. Further larger studies are needed to confirm the results and 
clarify a potential role of FGF-21 in the pathophysiology of T1DM. 
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 Figure 1. Basal and postprandial fibroblast growth factor-21 (FGF-21) concentrations in type 1 diabetic 
mellitus patients and healthy controls (Wilcoxon test). One patient had value of fasting FGF-21 of 842.4 
pg/mL and postprandial FGF-21 of 946 pg/mL, so those concentrations were not reported in the graph, 
but were included in statistics. 
 
 
 
 
 
 
   
Table 1. Demographics and biochemical parameters of type 1 diabetes mellitus patients (T1DM) and 
healthy controls.  
Variable T1DM patients 
(n=30) 
Healthy controls 
(n=9) 
No. of females/males 14/16 5/4 
Age (years) 37 (20-59) 30 (27-47) 
Disease duration (years) 22 (3-45)  
Body mass index (kg/m
2
) 24 (20-30) 25 (21-27) 
Glucose (mmol/L) 
   0’ (basal) 
   30’ (postprandial) 
 
6.9 (2.5-13.1) 
11.2 (3-19.5)
*
 
 
5.2 (4.3-5.8) 
6.2 (3.3-8.7) 
Insulin level (pmol/L) 
   0’ (basal) 
   30’ (postprandial) 
 
 
54.1 (17.8-116.8) 
356.6 (268.5-992.3) 
Hemoglobin A1c (%) 7.2 (5.1-12.4)
*
 5.2 (4.8-5.8) 
Total insulin requirement (IU/kg) 0.6 (0.3-0.9)  
Short-acting insulin requirement (IU/kg) 0.3 (0.2-0.6)  
Creatinine (µmol/L) 66 (43-88) 71 (43-114) 
LDL (mmol/L) 
   0’ (basal) 
   30’ (postprandial) 
 
2.9 (1.9-5) 
2.9 (2-4.7) 
 
3.1 (2.2-4.4) 
2.6 (2.1-3.7) 
HDL (mmol/L) 
   0’ (basal) 
   30’ (postprandial) 
 
1.6 (1-2.6) 
1.4 (0.9-2.5) 
 
1.5 (1-2.2) 
1.5 (1-2.1) 
VLDL (mmol/L) 
   0’ (basal) 
   30’ (postprandial) 
 
0.4 (0.2-1) 
0.4 (0.2-1) 
 
0.4 (0.3-0.9) 
0.7 (0.3-0.8) 
Tryglicerides (mmol/L) 
   0’ (basal) 
   30’ (postprandial) 
 
0.9 (0.4-2.2) 
1 (0.5-2.2) 
 
0.8 (0.6-2.1) 
1.3 (0.7-1.7) 
FGF-21 (pg/mL) 
   0’ (basal) 
   30’ (postprandial) 
   ∆ 30’-0’ (postprandial change) 
 
28.2 (0-842.4)
*
 
28.25 (0-946) 
-1.1 (-53.9-103.6)
*
 
 
104 (7.7-240.7) 
66 (4.8-136.5) 
-20.5 (-104.2-0.7) 
Data are presented as medians (minimum-maximum). 
*
 P<0.05 vs healthy controls by Mann-Whitney U test.  
†
 LDL= low density lipoprotein cholesterol, HDL= high density lipoprotein cholesterol, VLDL= very low 
density lipoprotein cholesterol, FGF-21= fibroblast growth factor-21. 
 
 
 
 
 
Table 2. Binary logistic regression of independent variable fibroblast growth factor-21 (FGF-21) in 
relation to studied group (healthy controls vs type 1 diabetes mellitus patients) as dependent variable. 
Independent variable 
Model A 
OR (95%CI) 
Model B 
OR (95% CI)
 
Model C 
OR (95% CI) 
FGF-21 (pg/mL) 
0’ (basal) 
30’ (postprandial) 
 
∆ 30’-0’ (postprandial change) 
 
1,001 (0.996-1.006) 
1 (0.995-1.005) 
 
0.945 (0.898-0.995)
*
 
 
1 (0.996-1.006) 
0.999 (0.994-1.004) 
 
0.942 (0.891-0.997)
*
 
 
1.002 (0.996-1.009) 
1.001 (0.995-1.007) 
 
0.827 (0.644-1.061) 
Model A= crude model. Model B= adjusted by age, gender and body mass index. Model C= adjusted by age, 
gender, body mass index and postprandial glucose. 
* 
P<0.05 
 
